THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS NO. 596/2014 AS IT FORMS.
Dr. Coughlin has served as a Director since 2022, assuming the role of Head of Research and Development in February 2024, driving the development of the pre|CISION™ platform .
Avacta appoints new Chief Executive Officer Christina Coughlin, MD PhD Clinical proof-of-concept demonstrated for Avacta s lead programme AVA6000 and proof-of-mechanism for the.
The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Cizzle Biotechnology Holdings PLC - London diagnostics.